The promise of CAR-T therapy in CLL and challenges in the field

The treatment landscape of chronic lymphocytic leukemia (CLL) has greatly transformed over the years with the introduction of several agents, including Bruton’s tyrosine kinase (BTK) inhibitors, the BCL-2 inhibitor venetoclax, and anti-CD20 antibodies. CAR-T cell therapy has also improved treatment options for patients with various other hematological malignancies, although there are several barriers to the use of CAR-T therapy in CLL.

In this exclusive podcast, you will hear from experts John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, and Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, who discuss the challenges of implementing CAR-T therapy in CLL, the promise of these agents, and more. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.

The post The promise of CAR-T therapy in CLL and challenges in the field appeared first on VJHemOnc.